JCM
URGN icon

Jacobi Capital Management’s UroGen Pharma URGN Stock Holding History

Jacobi Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-250
Closed -$5K – 1442
2021
Q1 		$5K Buy
+250
New +$5.31K ﹤0.01% 1130

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobi Capital Management's URGN Position: Q2 2021 in Review

Jacobi Capital Management sold out of UroGen Pharma (URGN) in Q2 2021, closing a stake of 250 shares — an estimated $5K sold.

Jacobi Capital Management first reported a position in URGN in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 82 funds tracked by Wall St. Rank hold URGN as of Q2 2021.

  • Jacobi Capital Management reported no remaining UroGen Pharma position as of Q2 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 250 UroGen Pharma shares in Q2 2021, an estimated $5K.
  • Jacobi Capital Management first reported a position in UroGen Pharma in Q1 2021 and held it in 1 quarter.
  • Jacobi Capital Management's UroGen Pharma position peaked at $5K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2021.

Based on Jacobi Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.